Clinical Trial Update: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating donor TGF-β NK cells in combination with Isatuximab for relapsed or refractory multiple myeloma; the study is active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Donor Immune Cells (TGF-β NK Cells) (donor TGF-β NK cells)
• Isatuximab (isatuximab)

Snippet

Sponsor: Elvira Umyarova | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING